Hedge Fund Seeks Higher Price For Qiagen As COVID-19 Boosts Sales
Executive Summary
Hedge fund Davidson Kempner advised Qiagen to ask for a higher acquisition price from Thermo Fisher Sciences as COVID-19 has increased demand for diagnostic products.